Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025
ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue guidance.
Preliminary Third Quarter Results and Recent Highlights
Core business revenue of $6.4 million in the third quarter of 2025.
Strategic Platform License SPL Program-related revenue of $0.4 million in the third quarter of 2025.
Total revenue of $6.8 million in the third quarter of 2025.
Gross margin of $5.2 million (77% gross margin) in the third quarter of 2025. Non-GAAP adjusted gross margin of 81% excluding SPL Program-related revenue and reserves for excess and obsolete inventory.
MaxCyte added one new SPL client, Moonlight Bio, in October, in addition to Adicet Bio and Anocca AB in July. The total number of SPL agreements stands at 32.
Total cash, cash equivalents and investments were $158.0 million as of September 30, 2025.
MaxCyte's third quarter results are preliminary, unaudited and subject to change in connection with the completion of MaxCyte's quarterly closing process and review procedures. As a result, these preliminary results may differ from the actual results that will be reflected in MaxCyte's consolidated financial statements for the quarter ended September 30, 2025.
The Company is rescheduling the release of its third quarter 2025 financial results and the related conference call to allow additional time to complete the review of certain technical accounting matters related to the testing of goodwill and long-lived assets for potential impairment in connection with the completion of its financial statements for the third quarter of 2025. This impairment testing takes into consideration certain recent developments including favorable announcements from SPL partners and does not impact financial results reported for prior quarters.
The following tables provide details regarding the sources of the Company's revenue for the periods presented.
Three Months Ended
September 30(Unaudited)
2025
2024
% Change
(in thousands, except percentages)
Instruments
$
1,376
$
1,764
(22%)
PAs and consumables
2,577
3,432
(25%)
Licenses
1,803
2,528
(29%)
Assay services
248
–
–
Other
402
416
(3%)
Total Core Revenue
$
6,406
$
8,140
(21%)
Program-Related
423
24
1,663%
Total Revenue
$
6,829
$
8,164
(16%)
In addition to revenue, management regularly reviews key business metrics to evaluate our business, measure performance, identify trends affecting our business, formulate financial projections and make strategic decisions. As of the dates presented, these key metrics were as follows:
Three Months Ended September 30,(Unaudited)
2025
2024
